‘Buy JSW Steel and JSPL’ advise two brokerages banking on Chinese stimulus, better prices
Nomura has initiated coverage on JSW Steel and JSPL with “buy” recommendations. The brokerage has a price target of ₹1,220 on JSW Steel and ₹1,200 on JSPL.
Uncategorized
CNBC-TV18 Morning Call: Netanyahu warns of Iran payback, SEBI tightens F&O norms, US dock workers strike day 2
From the latest on Middle East tensions, to SEBI tightening F&O norms, US dock workers strike and government internship scheme and more, here is all that you need to know in CNBC-TV18’s Morning Call
Bharat Forge in focus after Class-8 truck orders in North America surge to a 10-month high
Class 8 truck orders in North America rose to a 10-month high in September to 30,000 units. When compared to August, these orders were up 124%, while on a year-on-year basis, that number was down 3.5%.
The Marketbuzz Podcast: GIFT Nifty points to a gap-down; Dabur gets a downgrade
Marketbuzz Podcast: Indian markets may see a gap-down start according to the GIFT Nifty. Watch out for stocks like Angel One, BSE, Bharat Forge and others.
Japanese stocks rise as Prime Minister’s comments weaken yen
The yen tumbled about 2% against the dollar Wednesday, its worst day since June 2022, after Shigeru Ishiba said the economy isn’t ready for another hike.
Stock Market LIVE Updates: Indian indices to resume trading after holiday, Wall Street sees marginal gains amid escalating geopolitical tensions
Stock Market LIVE Updates: On Tuesday, Nifty traded within a 160-point range but ended slightly below the flat line, marking its third consecutive day of losses. The early weekly expiry of Nifty Bank and the financial services expiry contributed to…
US markets remain on the edge as middle east tensions rise, payroll data looms
Treasuries slid and the US dollar climbed after stronger-than-expected jobs numbers dampened Wall Street’s confidence that the Federal Reserve’s next interest-rate cut would be a big one.
Levi shares fall 10% in extended trading after paring guidance
Sales in the fiscal third quarter, which ended August 25, were slightly short of the average analyst estimate, while Levi’s Americas division posted a revenue decline in the period.
Dr. Reddy’s inks licensing pact with Gilead to commercialise HIV drug
Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) infection in heavily treatment-experienced adults facing multi-drug resistant HIV-1. The Dr. Reddy’s stock price settled at ₹6,750.85 on the NSE…
Anil Ambani’s Reliance Group forays into Bhutan, to set up 1,270 MW projects
The partnership will prioritise green energy generation, focusing on solar and hydropower initiatives while also exploring innovative green technologies.